This injectable drug acts as a dual GLP-1 and GIP receptor agonist, effectively mimicking hormones that naturally control appetite and blood sugar
or the deficiency of related acyl-CoA (such as propionyl-CoA carboxylase, isobutyryl-CoA dehydrogenase, isovaleryl-CoA dehydrogenase, and succinyl-CoA synthetase) which also have proven to cause the downregulation of free carnitines 11
Raman A, Fitch M, Hudes ML, Lustig RH, Murray CB, Ikeda JP, Fleming SE: Baseline correlates of insulin resistance in inner city high BMI African American children
Once reconstituted (for research peptide forms), use within the timeframe specified by the supplier, typically 2-4 weeks
Across trials, patients have shown reductions in LDL cholesterol (the bad kind), triglycerides, and improvements in overall cardiometabolic markers